A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.

Mark T J van BusselAhmad AwadaMaja J A de JongeMorten Mau SorensenDorte NielsenPatrick SchöffskiHenk M W VerheulBarbara SarholzKarin BerghoffSamer El BawabMirjam KuipersLars DamstrupIvan Diaz-PadillaJan H M Schellens

Published in: British journal of cancer (2020)

NCT02316197.

Keyphrases

protein kinase
circulating tumor
open label
cell free
single molecule
double blind
placebo controlled
nucleic acid
clinical trial
randomized controlled trial
circulating tumor cells